These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4447779)

  • 1. Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts.
    Forni G; Comoglio PM
    Br J Cancer; 1974 Oct; 30(4):365-9. PubMed ID: 4447779
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of murine plasmocytoma tumours with antibody activity by their respective specific antigens.
    Paraf A; Guérin-Marchand C; Aubry J; Dubert JM
    Ann Immunol (Paris); 1975; 126C(4):411-21. PubMed ID: 55094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic changes in mouse adenocarcinoma after treatment with a coupled tumor protein antigen (Lewis CTPA).
    Phillip MJ; Lewis AJ; Daily NH
    Oncology; 1973; 27(6):481-3. PubMed ID: 4742675
    [No Abstract]   [Full Text] [Related]  

  • 7. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
    Mokyr MB; Hengst JC; Przepiorka D; Dray S
    Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for a membrane carrier molecule common to embryonal and tumour-specific antigenic determinants expressed by a mouse transplantable tumour.
    Comoglio PM; Bertini M; Forni G
    Immunology; 1975 Aug; 29(2):353-64. PubMed ID: 51002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460.
    Comoglio PM; Forni G
    Int J Cancer; 1973 Nov; 12(3):613-25. PubMed ID: 4134007
    [No Abstract]   [Full Text] [Related]  

  • 10. Cell-mediated immunity in vitro against syngeneic mouse plasma tumour cells.
    Wagner H; Röllinghoff M
    Nat New Biol; 1973 Jan; 241(106):53-4. PubMed ID: 4540590
    [No Abstract]   [Full Text] [Related]  

  • 11. Growth of syngeneic tumours in unimmunized newborn and adult hosts.
    Forni G; Comoglio PM
    Br J Cancer; 1973 Feb; 27(2):120-7. PubMed ID: 4694385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of tumour growth with a defined glycoprotein antigen.
    Shier WT
    Nature; 1973 Jul; 244(5411):99-101. PubMed ID: 4583491
    [No Abstract]   [Full Text] [Related]  

  • 13. An analysis of T lymphocyte subsets in tumour-transplanted mice on the basis of Lyt antigenic markers and functions.
    Lala PK; McKenzie IF
    Immunology; 1982 Dec; 47(4):663-77. PubMed ID: 6982847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of the cell dose on the development of 2 transplantable tumors in a syngeneic host].
    Pugliese A; Choc O
    G Batteriol Virol Immunol; 1976; 69(1-6):122-31. PubMed ID: 15919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor immunoprophylaxis in mice using glutaraldehyde-treated syngeneic tumor cells.
    Frost P; Sanderson CJ
    Cancer Res; 1975 Oct; 35(10):2646-50. PubMed ID: 50879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and viral antigens of BALB-c myeloma.
    Krueger RG; Williams WH; Miller GC
    J Natl Cancer Inst; 1974 Apr; 52(4):1203-10. PubMed ID: 4133200
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.
    Röllinghoff M; Rouse BT; Warner NL
    J Natl Cancer Inst; 1973 Jan; 50(1):159-72. PubMed ID: 4571237
    [No Abstract]   [Full Text] [Related]  

  • 18. Preliminary observations on immunity in BALB-c mice to myeloma tumor of BALB-c origin.
    Shearer WT; Graff RJ; Eisen HN
    Transplantation; 1972 Mar; 13(3):345-7. PubMed ID: 5021442
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.